Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Improving Patient Outcomes Through Subtype Specific NCI-Sponsored Sarcoma Clinical Trials

Award Number: R50CA305003
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/04/2026
PERIOD OF PERFORMANCE END DATE: 08/31/2031

Group Awards By:

View Award Description

Improving Patient Outcomes Through Subtype Specific NCI-Sponsored Sarcoma Clinical Trials - PROJECT SUMMARY Dr. Steven Robinson, an Associate Professor of Oncology at Mayo Clinic, is focused on clinical and translational research that seeks to improve the care of patients with sarcoma. Dr. Robinson develops and conducts clinical trials designed to test novel approaches for treatment of sarcoma in a histologic subtype restricted design. Dr. Robinson is the study chair for two active NCTN trials: CTEP protocol 10056 (NCT02923778) in patients with localized high grade liposarcoma, leiomyosarcoma and undifferentiated pleomorphic sarcoma and Alliance protocol A092107 (NCT05694871), a randomized phase 2 trial in patients with locally advanced/metastatic dedifferentiated liposarcoma. Dr. Robinson is the corollary co-chair for A091902, an open-label multi-arm study in patients with advanced angiosarcoma. Dr. Robinson proposes to use this R50 application to: 1) complete the active clinical trials in which he is overall study PI (including the outcome and correlative biomarker analyses, drafting the abstracts and manuscripts, as well as generation of new concepts driven by the results of the respective corollary analyses); 2) Partner with junior investigators in the development of Alliance Sarcoma Working Group (SWG) approved concepts, through CTEP approval, protocol generation and activation, where he will also serve as Mayo Clinic Comprehensive Cancer Center (MCCCC) PI for these studies; 3) improve accrual of patients to sarcoma dedicated trials across the MCCCC through innovative approaches and strategic partnerships to raise trial awareness and enhance accrual accountability; and 4) increase the training and retention of academic medical oncologists through active engagement and mentoring of internal medicine residents. Dr. Robinson co-chairs the Sarcoma Working Group (SWG) for the Alliance and serves as both co- chair of the Development Research Program and on the administrative core for the multi-institutional Leiomyosarcoma SPORE (P50CA272170). These roles position Dr. Robinson to engage sarcoma clinician investigators and basic scientists to partner in developing subtype specific mechanistic driven studies with higher likelihood of successful clinical translation. Dr. Robinson will further utilize the R50 award to execute his role as Alliance SWG co-chair to increase NCTN inter-working group interactions, in both championing partner NCTN sarcoma trials through the Alliance and ongoing efforts to minimize duplication of new study development. The R50 will similarly protect the time required to execute his additional sarcoma national and institutional commitments as a member of the NCI sarcoma steering committee and MCCCC NCCN soft tissue and GIST guidelines representative. Finally, in addition to Dr. Robinson’s efforts within the MCCCC, he will leverage his Mayo Clinic residency and fellowship committee roles to formalize an active mentorship program, with the intent of early engagement leading to increased academic retention. Dr. Robinson is committed to serving the NCTN and meeting the mission of the NCI. The NCI Research Specialist (Clinician Scientist) R50 award would enable him to continue and expand his efforts to develop and complete high yield NCTN clinical trials in sarcoma.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $207,179 )
2026	2026	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	000	1	9/4/2026	NEW	$207,179
														Subtotal = $207,179

Grand Total All Awards = $207,179

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Improving Patient Outcomes Through Subtype Specific NCI-Sponsored Sarcoma Clinical Trials

Award Number: R50CA305003

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/04/2026

PERIOD OF PERFORMANCE END DATE: 08/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer